Please assess the completion status of the following clinical trial:

Trial Title: A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old at time of study entry (consent) and adult male or female (For Nebraska, ≥19 years old)~2. Histologically or cytologically confirmed ES-SCLC~3. Tumor biopsy or cytology should be obtained within 8 weeks of initiation of treatment.~4. Brain metastases; must be asymptomatic or treated and stable, off steroids for at least 1 month prior to study treatment.~5. Have not received any prior therapy for SCLC, except palliative radiation. If the patient received radiation, there must be measurable disease outside the radiation field.~6. Measurable disease or evaluable disease based on RECIST Version 1.1.~7. Eastern Cooperative Oncology Group ECOG = 2~8. Body weight \> 30 kg~9. No active secondary malignancy. Patients with other prior malignancies will be included, provided they have been disease-free for at least five years.~10. Adequate hematologic and end organ function~11. Women of childbearing potential must have a pregnancy test (urine or serum) proven negative within 14 days prior to registration.~Exclusion Criteria:~1. Participation in another clinical study with an investigational product during the last 28 days.~2. Any previous chemotherapy and /or immunotherapy for SCLC~3. Current or prior use (≤ 14 days before first doses of study drugs) of immunosuppressive medication.~4. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.~5. History of another primary malignancy except for malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP~6. History of leptomeningeal carcinomatosis~7. Paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic steroids or clinical symptomatology suggesting worsening of PNS~8. Active infection including tuberculosis, HIV, hepatitis B and C.~9. Active or prior documented autoimmune or inflammatory disorders~10. Uncontrolled cardiovascular disease~11. History of active primary immunodeficiency~12. Pregnant or lactating women~13. Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Durvalumab 1500 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab maintenance monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after Cycle 4.
- Cohort 2 (Type: EXPERIMENTAL): Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion every 3 weeks, starting on Week 7, for up to a maximum of 2 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion every 4 weeks, starting 4 weeks after the last infusion of the combination.

Based on this trial design, predict the completion outcome and termination type (if applicable).